Treatment of orbital myositis with adalimumab (Humira).
Adalimumab is a fully humanized IgG1 monoclonal antibody to tumor necrosis factor-a. We describe 2 patients (17 and 13 years of age) with refractory, steroid-dependent, recurrent nonspecific orbital myositis not controlled with standard immunosuppressive medications. Both improved with adalimumab treatment, allowing reduction in corticosteroid dosage without disease flare.
Division of Pediatric Rheumatology, Hospital for Special Surgery, New York, New York 10021, USA.
Alexa B
AB
Adams
Michael
M
Kazim
Thomas J A
TJ
Lehman
D000068879:Adalimumab; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D016727:Orbital Pseudotumor / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab